Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil D Perkins

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
The Biochemical Journal|October 14, 2022
Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potentialSuzanne Madgwick, Saimir Luli, Helene Sellier, et al.
The Biochemical Journal|October 14, 2022
Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cellsJill E Hunter, Amy E Campbell, Scott Kerridge, et al.
Hepatology (Baltimore, Md.)|September 22, 2012
Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune responseAnna Moles, Ana M Sanchez, Paul S Banks, et al.
The Journal of Biological Chemistry|June 14, 2005
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanismMaofu Fu, Chenguang Wang, Mahadev Rao, et al.
Molecular Cell|December 13, 2006
SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genesMakiko Fujii, Lyudmila A Lyakh, Cameron P Bracken, et al.
Hepatology (Baltimore, Md.)|September 11, 2022
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesisJack Leslie, Jill E Hunter, Amy Collins, et al.
The Biochemical Journal|October 14, 2022
Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistanceJill E Hunter, Amy E Campbell, Jacqueline A Butterworth, et al.
The Biochemical Journal|October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathwayJill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Nature Cancer|October 19, 2020
Age-associated mitochondrial DNA mutations cause metabolic remodelling that contributes to accelerated intestinal tumorigenesisAnna Lm Smith, Julia C Whitehall, Carla Bradshaw, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The Biochemical Journal|October 14, 2022
Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potentialSuzanne Madgwick, Saimir Luli, Helene Sellier, et al.
The Biochemical Journal|October 14, 2022
Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cellsJill E Hunter, Amy E Campbell, Scott Kerridge, et al.
Hepatology (Baltimore, Md.)|September 22, 2012
Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune responseAnna Moles, Ana M Sanchez, Paul S Banks, et al.
The Journal of Biological Chemistry|June 14, 2005
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanismMaofu Fu, Chenguang Wang, Mahadev Rao, et al.
Molecular Cell|December 13, 2006
SNIP1 is a candidate modifier of the transcriptional activity of c-Myc on E box-dependent target genesMakiko Fujii, Lyudmila A Lyakh, Cameron P Bracken, et al.
Hepatology (Baltimore, Md.)|September 11, 2022
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesisJack Leslie, Jill E Hunter, Amy Collins, et al.
The Biochemical Journal|October 14, 2022
Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistanceJill E Hunter, Amy E Campbell, Jacqueline A Butterworth, et al.
The Biochemical Journal|October 14, 2022
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathwayJill E Hunter, Amy E Campbell, Nicola L Hannaway, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Nature Cancer|October 19, 2020
Age-associated mitochondrial DNA mutations cause metabolic remodelling that contributes to accelerated intestinal tumorigenesisAnna Lm Smith, Julia C Whitehall, Carla Bradshaw, et al.
Pageof 9